Abstract: Novel compounds of formula I ##STR1## wherein R.sup.1 is independently hydrogen, hydroxy, alkyl with 1 to 6 carbon atoms, acyloxy groups with 1 to 6 carbon atoms, alkyloxy with 1 to 6 carbon atoms or from 1 to 5 sugar moieties; and R.sup.2 is independently hydrogen, or alkyl with 1 to 6 carbon atoms.The compounds are producible by aerobic cultivation on suitable nutrient media under suitable conditions of a strain of the fungus Ascochyta sp., subsequent recovery of the active component from the fermentation medium, and optionally modifying the active compound to obtain a compound of the desired formula I.Disclosed is also microorganisms capable of producing said compounds, compositions containing said compounds, and the use of such compositions for controlling fungi in valuable crops, animals, including birds and mammals, and in the preservation of wood, paints and edible products.

Abstract: The invention relates to a Bacillus thuringiensis strain(s) which solely produces a CryIA(a) crystal delta-endotoxin having a molecular weight of 130,000 daltons and is active against lepidopteran pests. The invention is also related to a spore(s), mutant(s), or crystal delta-endotoxin obtainable therefrom. Furthermore, the invention relates to insecticidal compositions comprising the B.t. strain, spore, mutant or crystal delta-endotoxin of the present invention. The invention further relates to methods of using the insecticidal compositions to control an insect pest(s) of the order Lepidoptera.

Abstract: A pharmaceutical formulation comprising a growth hormone and Lys-Gly-Asp-Ser (SEQ ID No: 1) as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.

Abstract: A pharmaceutical formulation comprising a growth hormone and valine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.

Abstract: A coagulation active complex of Factor VIII fragments is produced by causing a coagulation inactive FVIII heavy chain to react with a coagulation inactive FVIII light chain in the presence of a complex forming agent. Thus, FVIII-HC and FVIII-LC are converted to coagulation active FVIII complex in the presence of metal ions, such as Mn.sup.2+, Ca.sup.2+, or Co.sup.2+ or a component of the prothrombin complex or a substance having reactivity to compounds containing the group --SH and/or --S--S.

Abstract: A combination of GnRH analog, gonadotrophins, and growth hormone is very useful for treating infertility in higher mammals and humans since the probability of pregnancy is enhanced and the total doses of gonadotrophins are reduced. The treatment is initiated with administration of GnRH analog and continued with administration of gonadotrophins and growth hormone.

Abstract: The invention relates to a detergent composition comprising a protease and one or more other enzymes, as well as comprising a reversible protease inhibitor of the peptide or protein type.

Abstract: The invention is directed to a method for deinking and uncoating printed paper which comprises using a monocomponent cellulase during recycling.

Abstract: A plastein material is made by reversing the normal hydrolytic activity of a serine protease. The protease produces a plastein material by acting on a proteinaceous substrate. The substrate is preferably whey, casein or soy protein.

Abstract: A polypeptide for production in yeast comprises a fusion of a signal peptide, a leader peptide and a heterologous protein or polypeptide. The polypeptide is modified in its amino acid sequence adjacent to a yeast processing site positioned between the C-terminal end of the leader peptide and the N-terminal end of the heterologous protein so as to provide a presentation of the processing site which makes it accessible to proteolytic cleavage. Such a presentation is provided by adding one or more amino acids (at least one of which is negatively charged) to either the C-terminal end of the leader or the N-terminal end of the protein, or both. The heterologous protein may, for instance, be aprotinin or insulin precursor or an analogue thereof.

Abstract: Novel compounds of the general composition I, Lactate (1), Glycine (1), Valine (4), Isoleucine (1), pipecolic acid (1), Aspartic acid (1), Tyrosine (1), wherein each amino acid residue independently may occur in L- or D- form, and wherein the number in parenthesis indicates the number of occurrences of each moiety, and derivatives thereof are disclosed. The compounds are producible by aerobic cultivation on suitable nutrient media under suitable conditions of a strain of the fungus Curvularia sp., subsequent recovery of the active component from the fermentation medium, and optionally modifying the active compound to obtain a compound of the desired general composition. Disclosed are also microorganisms capable of producing said compounds, compositions containing said compounds, and the use of such compositions for controlling fungi in crops, and in the preservation of wood, paints, cosmetics, and edible products.

Abstract: Tricyclic benzazepines having the general formula ##STR1## wherein A together with the .alpha.- and .beta.-marked carbon atoms is a cyclopentene, cyclohexene, furan, dihydrofuran, pyran, dihydropyran, thiophene, oxazole, pyrrole, pyrroline, tetrahydropyridine or dioxole ring, R.sup.1 is H or alkyl, R.sup.2 and R.sup.3 independently are H, alkoxy, halogen, nitro, cyano or hydroxy, or R.sup.2 and R.sup.3 together may form a furan, dihydrofuran, cyclopentene or dioxole ring and R.sup.4 is H, alkoxy, nitro, cyano, hydroxy or halogen, or a pharmaceutically acceptable salt thereof, are useful in treatment of certain disorders in the central nervous system, e.g., psychosis, pain, depression, sleep disturbances, dyskinesia, Parkinson's disease, stroke.

Abstract: A polypeptide for production in yeast comprises a fusion of a signal peptide, a leader peptide and a heterologous protein or polypeptide. The polypeptide is modified in its amino acid sequence adjacent to a yeast processing site positioned between the C-terminal end of the leader peptide and the N-terminal end of the heterologous protein so as to provide a presentation of the processing site which makes it accessible to proteolytic cleavage. Such a presentation is provided by adding one or more amino acids (at least one of which is negatively charged) to either the C-terminal end of the leader or the N-terminal end of the protein, or both. The heterologous protein may, for instance, be aprotinin or insulin precursor or an analogue thereof.

Abstract: Patients with chronic liver disease and consequently very low concentrations of IGF-1 in the blood, in spite of increased GH concentrations, are treated with periodically injections of hGH for a period both parameters being individually adjusted for the patients.

Abstract: An isolated arabinofuranosidase from Bacillus stearothermophilus NRRL B-18659, Bacillus stearothermophilus NRRL B-18660 and Bacillus stearothermophilus NRRL B-18661 is disclosed. The arabinofuranosidase has a maximum activity at about pH 6.0 and at about 65.degree. C., maintains at least about 50% of its maximum activity at 70.degree. C. and pH 7.0 after 80 minutes, and has an isoelectric point of about 4.4. The arabinfuranosidase can be used in a method of hydrolyzing xylan present in wood pulp at temperatures of at least about 60.degree. C. and a pH of at least about 7.0. The arabinofuranosidase is used along with at least two xylanases and a xylosidase isolated from the above Bacillus stearothermophilus strains.

Abstract: An isolated xylosidase from Bacillus stearothermophilus NRRL B-18659, Bacillus stearothermophilus NRRL B-18660 and Bacillus stearothermophilus NRRL B-18661 is disclosed. The xylosidase has a maximum activity at about pH 6.0 and at about 75.degree. C., maintains at least about 60% of its maximum activity at about 65.degree. C. and pH 7 after 4 hours, is resistant to end-product inhibition maintaining over 75% of maximum activity in the presence of 1 molar xylose and has an isoelectric point of about 5.0. The xylosidase can be used in a method of hydrolyzing xylan present in wood pulp at temperatures of at least about 60.degree. C. and a pH of at least about 7.0. The xylosidase is used along with at least two xylanases and an arabinofuranosidase isolated from the above Bacillus stearothermophilus strains.

Abstract: 2,3,4,5-Tetrahydro-1H-3-benzazepines having the general formula ##STR1## wherein R.sup.1 is Cl or Br; R.sup.3 and R.sup.4 are hydrogen, halogen, CF.sup.3, CN, NO.sub.2, or NH.sub.2.The compounds are useful in treatment of certain disorders in the central nervous system.

Abstract: Ala-Glu-IGF-I is a novel compound which exerts IGF-I activity and is a precursor for the preparation of IGF-I. Ala-Glu-IGF-I may by converted to IGF-I by renaturation after recombinant production in E. coli under specified conditions and then cleaving Ala-Glu from the IGF-I.

Abstract: Novel compounds of formula I ##STR1## wherein R.sup.1 is independently hydrogen, hydroxy, alkyl with 1 to 6 carbon atoms, acyloxy groups with 1 to 6 carbon atoms, alkyloxy with 1 to 6 carbon atoms or from 1 to 5 sugar moleties; and R.sup.2 is independently hydrogen, or alkyl with 1 to 6 carbon atoms.The compounds are producible by aerobic cultivation on suitable nutrient media under suitable conditions of a strain of the fungus Ascochyta sp., subsequent recovery of the active component from the fermentation medium, and optionally modifying the active compound to obtain a compound of the desired formula I.Disclosed is also microorganisms capable of producing said compounds, compositions containing said compounds, and the use of such compositions for controlling fungi in valuable crops, animals, including birds and mammals, and in the preservation of wood, paints and edible products.

Abstract: A polypeptide for production in yeast comprises a fusion of a signal peptide, a leader peptide and a heterologous protein or polypeptide. The polypeptide is modified in its amino acid sequence adjacent to a yeast processing site positioned between the C-terminal end of the leader peptide and the N-terminal end of the heterologous protein so as to provide a presentation of the processing site which makes it accessible to proteolytic cleavage. Such a presentation is provided by adding one or more amino acids (at least one of which is negatively charged) to either the C-terminal end of the leader or the N-terminal end of the protein, or both. The heterologous protein may, for instance, be aprotinin or insulin precursor or an analogue thereof.